Introduction

CME Overview

R.N. Weinreb: Glaucoma neuroprotection

Current management of glaucoma
The need for glaucoma neuroprotection
Challenges in developing a neuroprotactive drug in glaucoma
Keypoints

J. Crowston: Biology of neuronal death

Cell body death
Axon death
Mechanisms that may modulate the vulnerability of cells in glaucoma
Keypoints

N. Gupta: Is glaucoma a brain disease?

Dendrite pathology in the LGN
Are changes in the CNS relevant?
Keypoints

C. Girkin: Glaucoma progression in clinical practice – visual funtion

High inter-test variability of SAP
Poor sensitivity of SAP
Keypoints

R. Hitchings: Patient’s perception of progression and changes in binocular fields

Overlapping defects in the binocular visual field
Rapid progression
Keypoints

D.S. Greenfield: Measuring glaucoma structural progression in clinical practice

Optic disc photography
Quantitative imaging technologies
Case study : progression of glaucoma
Keypoints

M. Vidal-Sanz: Neuroprotection with alpha-2 agonists

Retinal ganglion cells
Inner and outer retina
Retino-tectal projection
Keypoints

J. Liebmann: The Low-Pressure Glaucoma Treatment Study

Keypoints

S.A. Lipton: Memantine – A clinically-tolerated, neuroprotective NMDA receptor antagonist

The NMDA receptor
Memantine
Keypoints

Y. Yücel: Memantine : Neuroprotection in animal studies

Memantine
Keypoints

M.R. Wilson: Which patients might benefit from a glaucoma neuroprotective agent?

Keypoints

I. Goldberg: Clinical experience with NMDA receptor antagonists

Potential use of neuroprotection in glaucoma
Clinical use of memantine
Keypoints

Discussion

Neuroprotection in Glaucoma – Post-Test Form